|Bid||129.84 x 900|
|Ask||136.00 x 800|
|Day's range||132.07 - 132.54|
|52-week range||117.58 - 212.00|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.
Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?